Trends in antimicrobial drug development: Implications for the future
Trends in antimicrobial drug development: Implications for the future
复制标题
DOI：
10.1086/420937
复制
发表时间：
2004-05-01
影响因子：
11.8
通讯作者：
Edwards, JE
中科院分区：
文献类型：
--
作者：
Spellberg, B;Powers, JH;Edwards, JE
由于常见病原体出现多药耐药性、新感染的迅速出现以及多药耐药制剂在生物武器中的潜在使用，对新抗菌剂的需求比以往任何时候都大。讽刺的是，一些制药公司已经表示，他们正在削减抗感染研究项目。我们评估了美国食品药品监督管理局（FDA）批准药物的数据库以及世界上最大的制药和生物技术公司的研究和开发计划，以记录新抗菌药物开发的趋势。在过去的20年里，FDA批准的新抗菌剂减少了56%（1998 - 2002年与1983 - 1987年相比）。预测未来的发展，新的抗菌药物构成了最大的制药和生物技术公司开发计划中披露的506种药物中的6种。尽管迫切需要新的抗微生物剂，但这些药物的开发正在下降。需要鼓励和促进开发新的抗微生物剂的解决方案。
The need for new antimicrobial agents is greater than ever because of the emergence of multidrug resistance in common pathogens, the rapid emergence of new infections, and the potential for use of multidrug-resistant agents in bioweapons. Paradoxically, some pharmaceutical companies have indicated that they are curtailing anti-infective research programs. We evaluated the United States Food and Drug Administration (FDA) databases of approved drugs and the research and development programs of the world's largest pharmaceutical and biotechnology companies to document trends in the development of new antimicrobial agents. FDA approval of new antibacterial agents decreased by 56% over the past 20 years ( 1998 - 2002 vs. 1983 - 1987). Projecting future development, new antibacterial agents constitute 6 of 506 drugs disclosed in the developmental programs of the largest pharmaceutical and biotechnology companies. Despite the critical need for new antimicrobial agents, the development of these agents is declining. Solutions encouraging and facilitating the development of new antimicrobial agents are needed.